Enfuvirtide Added to an Optimized Antiretroviral Regimen Provided Significant Benefits in Patients with Multidrug-Resistant HIV Infection

Lorber, Bennett
December 2004
Annals of Internal Medicine;12/7/2004, Vol. 141 Issue 11, p877
Academic Journal
The article presents information on papers related to infectious diseases in the U.S. The paper "Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America," by J.P. Lalezari, K. Henry, M. O'Hearn et al. studied that enfuvirtide added to an optimized antiretroviral regimen provided significant benefits in patients with multidrug-resistant HIV infection. This randomized, open-label, phase 3 study of enfuvirtide involved 501 patients from 48 sites in the United States, Canada, Mexico and Brazil.


Related Articles

  • The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention. Altice, Frederick L.; Sullivan, Lynn E.; Smith-Rohrberg, Duncan; Basu, Sanjay; Stancliff, Sharon; Eldred, Lois // Clinical Infectious Diseases;12/15/2006 Supplement, Vol. 43, pS178 

    Untreated opioid dependence is a major obstacle to the successful treatment and prevention of human immunodeficiency virus (HIV) infection. In this review, we examine the interwoven epidemics of HIV infection and opioid dependence and the emerging role of buprenorphine in improving HIV treatment...

  • Corroborative Study Confirmed That Adding Enfuvirtide to an Optimized Antiretroviral Regimen Benefited Patients with Multidrug-Resistant HIV Infection. Lorber, Bennett // Annals of Internal Medicine;12/7/2004, Vol. 141 Issue 11, p878 

    The article presents information on papers related to infectious diseases in Europe and Australia. The paper "Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia," by A. Lazzarin, B. Clotet, D. Cooper, et al. confirmed that adding enfuvirtide to an...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Oct2005, Vol. 19 Issue 10, p696 

    Reports several developments related to antiviral agents worldwide. Accounts on the reaction of HIV viral load to ritonavir-boosted atazanavir used as monotherapy; Analysis by Great Britain researchers on the benefit of highly active antiretroviral therapy when compared to no treatment in...

  • A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Sullivan, Lynn E.; Barry, Declan; Moore, Brent A.; Chawarski, Marek C.; Tetrault, Jeanette M.; Pantalon, Michael V.; O'Connor, Patrick G.; Schottenfeld, Richard S.; Fiellin, David A. // Clinical Infectious Diseases;12/15/2006 Supplement, Vol. 43, pS184 

    Background. Untreated opioid dependence adversely affects the care of human immunodeficiency virus (HIV)-positive patients. Buprenorphine, a partial opioid agonist, is available for maintenance treatment of opioid dependence in HIV specialty settings. We investigated the feasibility and efficacy...

  • Patient factors to target for elimination of mother-to-child transmission of HIV. Mnyani, Coceka N.; Simango, Adonia; Murphy, Joshua; Chersich, Matthew; McIntyre, James A. // Globalization & Health;2014, Vol. 10 Issue 1, p1 

    Background There is great impetus to achieve elimination of mother-to-child transmission of HIV (eMTCT) by 2015, and part of this is to identify factors to target to achieve the goal. This study thus identified key patient factors for MTCT in a high HIV prevalence setting in Johannesburg, South...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Jan2005, Vol. 19 Issue 1, p58 

    The article focuses on antiviral agents for AIDS and sexually transmitted diseases. Researchers at Harvard Medical School have observed limited durability of viral control following treatment of patients with acute HIV infection. Good treatment response was also achieved for ritonavir-boosted...

  • Predictors of Renal Outcome in HIV-Associated Nephropathy. Post, Frank A.; Campbell, Lucy J.; Hamzah, Lisa; Collins, Lisa; Jones, Rachael; Siwani, Rizwan; Johnson, Leann; Fisher, Martin; G.^Holt, Stephen; Bhagani, Sanjay; Frankel, Andrew H.; Wilkins, Edmund; Ainsworth, Jonathan G.; Larbalestier, Nick; Macallan, Derek C.; Banerjee, Debasish; Baily, Guy; Thuraisingham, Raj C.; Donohoe, Paul; Hendry, Bruce M. // Clinical Infectious Diseases;4/15/2008, Vol. 46 Issue 8, p1282 

    Background. Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN) is an important cause of end-stage renal disease among African American patients. This study was performed to study the epidemiology of HIVAN in a predominantly black African population and the impact of highly active...

  • Increased Rate of CD4+ T-Cell Decline and Faster Time to Antiretroviral Therapy in HIV-1 Subtype CRF01•AE Infected Seroconverters in Singapore. Oon Tek Ng; Li Lin; Laeyendecker, Oliver; Quinn, Thomas C.; Yong Jiang Sun; Cheng Chuan Lee; Yee Sin Leo // PLoS ONE;2011, Vol. 6 Issue 1, p1 

    Background: It remains controversial as to whether HIV-1 subtypes influence disease progression. Singapore offers a unique opportunity to address this issue due to the presence of co-circulating subtypes. We compared subtype CRF01_AE and non- CRF01_AE infected patients, with regards to estimated...

  • Delayed Progression to Death and to AIDS in a Hong Kong Cohort of Patients with Advanced HIV Type 1 Disease During the Era of Highly Active Antiretroviral Therapy. Ka Hing Wong; Kenny Chi Wai Chan; Shui Shan Lee // Clinical Infectious Diseases;9/15/2004, Vol. 39 Issue 6, p853 

    Background. The magnitude of the impact of highly active antiretroviral therapy (HAART) since its introduction in non-Western countries is not entirely clear. We studied disease progression among adult patients with advanced human immunodeficiency virus type 1 (HIV-1) infection in the pre-HAART...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics